New Multiple Sclerosis Clinical Trial Data Top SPT Week in Review

5. FDA OKs New Dosage Strength of Buprenorphine and Naloxone Sublingual Film

Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film for the maintenance treatment of opioid dependence. Read more.

4. Potential Hepatitis B Therapy Reduces Virus Surface Antigen in Clinical Trial

In its multiple-ascending dose trial, ARO-HBV demonstrated reductions in circulating hepatitis B virus surface antigen. Read more.

3. FDA Grants Breakthrough Therapy Designation to Tezepelumab for Severe Asthma

Treatment with tezepelumab reduced annual asthma exacerbation rates in patients with severe asthma without an eosinophilic phenotype. Read more.

2. Drug Used to Treat IBD, Arthritis Linked to Increased Skin Cancer Risk

Study identifies a potential association between azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma. Read more.

1. Ibudilast Reduces Brain Shrinkage in Progressive MS in Phase 2 Trial

Treatment with ibudilast reduced the progression of brain atrophy in patients with progressive multiple sclerosis compared with a placebo. Read more.